Clinical trials: Coagulation
Autoimmune Thrombocytopenic Purpura
Study of the Effectiveness of Rituximab in Adults With Chronic and Severe Immune Thrombocytopenic Purpura and Candidate for a Splenectomy
The goal of this study is to evaluate the clinical effectiveness of the rituximab at the adults with a chronic immune thrombocytopenic purpura (>=6 months of evolution) and severe (platelets <= 30x109/L) and candidate to a…
- Trial name
- NCT00225875
- Testing
- Mabthéra
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
ITP - Immune Thrombocytopenia
Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
It is a single-center, single-arm, open-labeled clinical trial to evaluate the efficacy and safety of CAR-T cells therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP).
- Trial name
- NCT06352281
- Testing
- CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Essential Thrombocythemia
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated.
- Trial name
- NCT06456346
- Testing
- Bomedemstat, Hydroxyurea
- Where
- 171 sites in United States, Argentina and 21 more
- Volunteers
- 300 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Immune Thrombocytopenia
A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a rare disease that results in low levels of platelets - the cells that help blood clot.
- Trial name
- NCT04278924
- Testing
- TAK-079
- Where
- 55 sites in United States, Bulgaria and 9 more
- Volunteers
- 41 people
- Sponsor
- Takeda
Coagulation Disorder
Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
A single centre, double-blind, randomized, parallel group, placebo-controlled study in healthy subjects conducted in two parts: Part 1: Single ascending doses in healthy subjects aged 18 to 49 years to assess safety…
- Trial name
- NCT05152420
- Testing
- VMX-C001, Apixaban, Rivaroxaban
- Where
- Netherlands
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.
Hemorrhage; Complicating Delivery, Coagulation Defect
The Effect of Human Albumin on Coagulation Competence and Hemorrhage
In a randomized clinical trial, the purpose is to investigate if perioperative coagulation and hemorrhage is influenced by colloid or crystalloid.
- Trial name
- NCT02270723
- Testing
- 5% Human Albumin " Behring", Lactated Ringer
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Kirsten Cleemann Rasmussen
Kidney Diseases, End Stage Renal Disease
Non- Clinical Coagulation Activation During Hemodialysis
Every patient included in the study will undergo 1 conventional hemodialysis treatment, ie 1 study visit. During the conventional hemodialysis treatment lasting 4 hours, 2 blood samples will be taken at different time points (5…
- Conditions
- Kidney Diseases, End Stage Renal Disease, Hemodialysis Complication
- Trial name
- NC-Coact (NCT04063423)
- Testing
- blood sample
- Where
- Belgium
- Volunteers
- 32 people
- Sponsor
- Universitair Ziekenhuis Brussel
Idiopathic Thrombocytopenic Purpura
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
This study will compare the efficacy, safety, and pharmacokinetics of standard treatment versus standard treatment plus MabThera in patients with ITP.
- Trial name
- NCT00770562
- Testing
- rituximab, Dexamethasone
- Where
- 22 sites in Italy
- Volunteers
- 103 people
- Sponsor
- Hoffmann-La Roche
Polycythemia Vera, Thrombocythemia, Essential
Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure
Myeloproliferative neoplasms (MPN) such as Polycythemia Vera (PV) and, Essential Thrombocythaemia (ET) are rare clonal myeloid neoplasms associated with an increased risk of both venous and arterial thrombosis.
- Trial name
- MPNClot (NCT02912884)
- Testing
- No cytoreductive vs cytoreductive drugs
- Where
- 2 sites in Switzerland, United Kingdom
- Volunteers
- 80 people
- Sponsor
- Dr Yan Beauverd
Hemophilia a
A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)
This study will compare bone mineral density in patients with severe hemophilia A receiving prophylaxis with emicizumab or efanesoctocog alfa.
- Trial name
- NCT07582276
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Arkansas Children's Hospital Research Institute
Hemostatic Disorders
Blood Products Transfusion in Cardiac Surgery After the Implementation of a Coagulation Monitoring System at Patient Bedside: Thromboelastometry Versus Standard Transfusion Protocol
Main objective: Determine whether by introducing thromboelastograph, the investigators reduced the number of packed red cells received by each patient (median) compared to the usual protocol, in which the indication for…
- Trial name
- ROTEM-2010 (NCT01919840)
- Testing
- Group ROTEM, Group C
- Volunteers
- 49 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Hemophilia A
Study Evaluating The Safety Of Xyntha In Usual Care Settings
The purpose of this study is to collect safety information associated with the use of Xyntha in a usual care setting. Upon meeting eligibility criteria, patients will be required to have approximately 5 study visits over a 2 year…
- Trial name
- NCT00765726
- Testing
- Moroctocog alfa(AF-CC), Blood draw for laboratory testing
- Where
- 6 sites in United States, New Zealand
- Volunteers
- 12 people
- Sponsor
- Pfizer
Immune Thrombocytopenia
A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)
The main purpose of this study is to assess the efficacy and safety of LIV-GAMMA SN Inj. in adult subjects with ITP. The primary objective of this study is to determine the responder rate.
- Trial name
- NCT03164915
- Testing
- LIV-GAMMA SN Inj.
- Where
- 6 sites in South Korea
- Volunteers
- 37 people
- Sponsor
- SK Plasma Co., Ltd.
Chronic Myeloproliferative Disorders, Leukemia
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
RATIONALE: Donor peripheral stem cell transplantation may be able to replace bone marrow and immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00080925
- Testing
- filgrastim, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Thromboembolism
Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT
Blood clots contribute to the death of at least 100,000 Americans each year. Because many of these deaths occur suddenly where treatment is impossible, the best treatment is prevention.
- Trial name
- GIFT (NCT01006733)
- Testing
- Pharmacogenetic, Target INR 1.8
- Where
- 6 sites in United States
- Volunteers
- 1,598 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Primary Thrombocytosis
The Role of Circ0014614 in the Formation and Development of ET
Research on the Role of Circ0014614 in the Formation and Development of ET
- Trial name
- NCT05921838
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Immune Thrombocytopenia
Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia
Immune Thrombocytopenia (ITP) is a disorder resulting in impaired platelet production and enhanced destruction on the basis of autoantibody-mediated mechanisms. Patients with ITP are at increased risk of bleeding and infection.
- Trial name
- NCT03520049
- Testing
- Oseltamivir
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Unity Health Toronto
Von Willebrand Disease
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B
To evaluate the effect of ARC1779, a therapeutic oligonucleotide ("aptamer") in patients with Type2B von Willebrand Disease.
- Trial name
- NCT00694785
- Testing
- ARC1779
- Volunteers
- 2 people
- Sponsor
- Archemix Corp.
Hemophilia
Hemophilia Mobile App Usability Pilot
The purpose of this study is to evaluate the utility and user experience of a smart phone app for people with medical conditions, used in conjunction with an ActiGraph wearable device and a connected scale.
- Trial name
- NCT03168685
- Testing
- SureSource Engage application
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Healthcare Innovation Technology Lab
Immune Thrombocytopenia (ITP)
Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP
Randomized, open-label, multicentre study to assess the efficacy and safety of the combination of low-dose rituximab and Iguratimod in patients with steroid-resistant/relapsed ITP.
- Trial name
- NCT07057778
- Testing
- Iguratimod, low-dose rituximab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.